IOSR Journal of Pharmacy (IOSRPHR), www.iosrphr.org

IOSR Journal of Pharmacy

Vol. 2, Issue 1, Jan-Feb.2012, pp. 081-082

IOSR

ENHANCEMENT OF ENTRAPMENT EFFICIENCY OF POROUS
CHITOSAN SCAFFOLD FORMULATION BY THE ADDITION OF

PEG 4000

Tarun Garg*, Arsh Chanana, Govind Sharma

Seth G.L.Bihani S.D. college of technical education, Sri Ganganagar

INTRODUCTION

Porous scaffold formulation is used for delivering the drug continuously to the target place but the major limitation face that
poor entrapment efficiency. The objective of this study was enhancement of entrapment efficiency of porous chitosan
scaffold formulation with the help of PEG 4000.

MATERIALS AND METHODS

POROUS CHITOSAN SCAFFOLD PREPARATION

Briefly different concentration of chitosan and PEG 4000 were dissolved in 0.2 M glacial acetic acid and mixture of solution
was poured into stainless steel mould and mould was stored in deep freezer at - 70°C for 5 days. After 5 days, mould was
placed in lyophiliser (Martin Christ alpha 1-2 LD plus, Germany) for 3 days. After 3 days, blank porous chitosan scaffold
was prepared. Gliclazide (GLZ) drug (0.1%) was dissolved in ethanol and poured into porous matrix scaffold with the help of
pipette using a post seeding method and drug loaded porous chitosan scaffold formulation was prepared [1].

ENTRAPMENT EFFICIENCY OF SCAFFOLD FORMULATIONS

Briefly, one piece of scaffold formulations was placed in 10 ml centrifuge tube, which was filled with PBS (pH 7.4) solution,
for 20 minute at 5000 rpm centrifugation speed, in centrifuge machine (Remi R-8C). Absorbance of supernatant was checked
at the Amax. Value of 226.5 nm using UV-VIS spectrophotometer (Shimadzu UV 1700). PBS was used as a control. The %
entrapment efficiency of the scaffold formulations were calculated from the following equation. Entrapment efficiency (%) =
D L - D F / D L x 100, where D L andD F are initial drug loaded (mg) and free drug (mg) respectively [2].

RESULTS AND DISCUSSION

ENTRAPMENT EFFICIENCY OF GLICLAZIDE LOADED CHITOSAN SCAFFOLD FORMULATIONS

6 different scaffold formulations were examined for entrapment efficiency. The effects of processing parameters such as
polymer concentration, PEG 4000 concentration on the GLZ entrapment efficiency (EE) of scaffold formulations are
presented in Table 1 . It was observed that the EE of GLZ increased with an increase in the PEG 4000 concentration from -

2.5%.

Table 1. Effects of various processing parameter on entrapment efficiency of GLZ in chitosan-PEG 4000 porous scaffold.

Each data point represents a mean ± standard deviation (n=3).

Formulation No.

Chitosan (%)

PEG 4000 (%)

Entrapment efficiency (%)

F1A

60.52 ± 2.49

F2A

0.5

66.64 ±2.65

F3A

1.0

69.46+2.03

F4A

1.5

72.68 ±2.23

F5A

2.0

74.76 ±1.98

F6A

2.5

75.10 ±2.02

ISSN: 2250-3013 www.iosrphr.org 81IPage

IOSR Journal of Pharmacy

Vol. 2, Issue 1, Jan-Feb.2012, pp. 081-082

IOSR

Fig 1. Entrapment efficiency of gliclazide loaded scaffold formulation (mean ± S.D., n=3)

Drug entrapment efficiency of scaffold formulations prepared with 1% chitosan with increasing concentration of PEG 4000
(0-2.5%) showed variable drug entrapment efficiency. Increasing concentration of PEG 4000 from 0-2.5%, increased %
drug entrapment efficiency in scaffold formulations prepared with 1% chitosan. This is obviously due to the formation of
high porous structure and more drugs were entrapped in it.

CONCLUSIONS

From this study, we concluded that, versatile carrier system i.e. porous scaffold formulation is effective for the delivery of
gliclazide for long duration of time period because entrapment efficiency of porous chitosan scaffold increased by the
addition of PEG 4000.

REFERENCES

[1] S.V. Madihally, H.W.T. Matthew, Porous chitosan scaffolds for tissue engineering, Biomaterials, 20, 1999,

1133-1142.

[2] P.V. Devarajan, G.S. Sonavane, Preparation and in- vitro/in- vivo evaluation of gliclazide loaded eudragit

nanoparticles as a sustained release carriers, Drug Development and Industrial Pharmacy, 3 3, 2007, 101-1 11.

ISSN: 2250-3013

www.iosrphr.org

82 I P a g e